0.30
+0.0185(+6.48%)
Currency In USD
| Previous Close | 0.29 |
| Open | 0.23 |
| Day High | 0.41 |
| Day Low | 0.23 |
| 52-Week High | 4 |
| 52-Week Low | 0.17 |
| Volume | 107.39M |
| Average Volume | 2.31M |
| Market Cap | 62.99M |
| PE | -0.15 |
| EPS | -2.09 |
| Moving Average 50 Days | 0.29 |
| Moving Average 200 Days | 0.68 |
| Change | 0.02 |
If you invested $1000 in Cyclacel Pharmaceuticals, Inc. (CYCC) 10 years ago, it would be worth $0.1 as of April 30, 2025 at a share price of $0.304. Whereas If you bought $1000 worth of Cyclacel Pharmaceuticals, Inc. (CYCC) shares 5 years ago, it would be worth $4.86 as of April 30, 2025 at a share price of $0.304.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Cyclacel Pharmaceuticals Announces $1 Million Private Placement Offering of Convertible Preferred Stock
GlobeNewswire Inc.
Mar 24, 2025 11:30 AM GMT
KUALA LUMPUR, Malaysia, March 24, 2025 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. ("Cyclacel") (NASDAQ: CYCC, NASDAQ: CYCCP), a biopharmaceutical company that develops innovative cancer medicine, today announced that it has entered into a s
Cyclacel Pharmaceuticals Announces Closing of a Change of Control Transaction and Appointment of New Executive Leadership
GlobeNewswire Inc.
Feb 27, 2025 6:38 PM GMT
BERKELEY HEIGHTS, N.J., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. ("Cyclacel") (NASDAQ: CYCC, NASDAQ: CYCCP), a biopharmaceutical company that develops innovative cancer medicines, today announced a change in control and lead
Cyclacel Pharmaceuticals Announces Agreement for the Acquisition of Preferred Stock by David Lazar
GlobeNewswire Inc.
Jan 03, 2025 2:01 PM GMT
David Lazar agrees to invest $3.1 million in Preferred Stock and becomes Interim CEOBERKELEY HEIGHTS, N.J., Jan. 03, 2025 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company") today announced